|
Sign In to gain access to subscriptions and/or personal tools.
|
A Robust, Target-Driven, Cell-Based Assay for Checkpoint Kinase 1 Inhibitors
Tsuyoshi Ishii
GlaxoSmithKline K.K., Tsukuba-shi Ibaraki, Japan
Hiroshi Sootome
Bioscience Department GlaxoSmithKline K.K. 43 Wadai, Tsukuba-shi Ibaraki 300-4247, Japan, hiroshi_sootome{at}merck.com
Alastair J. King
GlaxoSmithKline, Upper Providence, Pennsylvania
Mikiya Suda
GlaxoSmithKline K.K., Tsukuba-shi Ibaraki, Japan, Molecular Medicine Research Laboratories, Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Ibaraki, Japan
Nobuhiro Noro
GlaxoSmithKline K.K., Tsukuba-shi Ibaraki, Japan
Keizo Yamashita
GlaxoSmithKline K.K., Tsukuba-shi Ibaraki, Japan
Takato Noumi
GlaxoSmithKline K.K., Tsukuba-shi Ibaraki, Japan
Checkpoint kinase 1 (Chk1), a serine/threonine kinase, plays an important role in DNA damage checkpoint control and is an attractive target for cancer treatment. To develop a Chk1-specific cell-based assay, stable clones were established in which Chk1 kinase domain fused at its N-terminus with p53 through 4 tandem repeats of Gly-Gly-Gly-Gly-Ser was expressed in an inducible manner. Chk1 kinase specificity of the phosphorylation of fused p53 was confirmed by the experiments with a kinase-inactive Chk1. Only in the presence of an inducer molecule was phosphorylation of p53 at Ser-15 in the stable clones induced. Furthermore, its assay performance proved acceptable for high-throughput screening applications, judging from the Z' factor values (> 0.77). Finally, the cell-based assay thus established yielded structure-activity relationship data for a small set of test inhibitors of Chk1 within cells. Collectively, these results demonstrate that the established cell-based assay provides a novel and highly sensitive cellular platform for Chk1 inhibitor discovery. (Journal of Biomolecular Screening 2007:809-817)
Key Words: checkpoint kinase 1 GeneSwitch system target specific cell-based assay
References
- Liu Q., Guntuku S., Cui XS, Cortez G., Tamai K., Luo G., et al: Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint . Genes Dev 2000;14: 1448-1459 .[Abstract/Free Full Text]
- Dixon H., Norbury CJ: Therapeutic exploitation of checkpoint defects in cancer cells lacking p53 function . Cell Cycle 2002;1: 362-368 .[Medline]
[Order article via Infotrieve]
- Tao ZF, Lin NH: Chk1 inhibitors for novel cancer treatment . Anticancer Agents Med Chem 2006;6: 377-388 .[Medline]
[Order article via Infotrieve]
- Sausville EA, Arbuck SG, Messmann R., Headlee D., Bauer KS, Lush RM, et al: Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms . J Clin Oncol 2001;19: 2319-2333 .[Abstract/Free Full Text]
- Ou YH, Chung PH, Sun TP, Shieh SY: p53 C-terminal phosphorylation by CHK1 and CHK2 participates in the regulation of DNA-damage-induced C-terminal acetylation . Mol Biol Cell 2005;16: 1684-1695 .[Abstract/Free Full Text]
- Maki CG, Huibregtse JM, Howley PM: In vivo ubiquitination and proteasome-mediated degradation of p53(1) . Cancer Res 1996;56: 2649-2654 .[Abstract/Free Full Text]
- Honda R., Yasuda H.: Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53 . EMBO J 1999; 18: 22-27 .[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Oren M.: Regulation of the p53 tumor suppressor protein . J Biol Chem 1999;274: 36031-36034 .[Free Full Text]
- Ashcroft M., Kubbutat MH, Vousden KH: Regulation of p53 function and stability by phosphorylation . Mol Cell Biol 1999;19: 1751-1758 .[Abstract/Free Full Text]
- Liu AM, Ho MK, Wong CS, Chan JH, Pau AH, Wong YH: Galpha(16/z) chimeras efficiently link a wide range of G protein-coupled receptors to calcium mobilization . J Biomol Screen 2003;8: 39-49 .[Abstract/Free Full Text]
- Storz P., Doppler H., Horn-Muller J., Groner B., Pfizenmaier K., Muller G.: A cellular reporter assay to monitor insulin receptor kinase activity based on STAT 5-dependent luciferase gene expression . Anal Biochem 1999; 276: 97-104 .[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Wood JM, Bold G., Buchdunger E., Cozens R., Ferrari S., Frei J., et al: PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration . Cancer Res 2000;60: 2178-2189 .[Abstract/Free Full Text]
- Quinones A., Rainov NG: Identification of genotoxic stress in human cells by fluorescent monitoring of p53 expression . Mutat Res 2001;494: 73-85 .[Web of Science][Medline]
[Order article via Infotrieve]
- Dikov MM, Reich MB, Dworkin L., Thomas JW, Miller GG: A functional fibroblast growth factor-1 immunoglobulin fusion protein . J Biol Chem 1998;273: 15811-15817 .[Abstract/Free Full Text]
- Sakurai H., Nishi A., Sato N., Mizukami J., Miyoshi H., Sugita T.: TAK1-TAB1 fusion protein: a novel constitutively active mitogen-activated protein kinase kinase kinase that stimulates AP-1 and NF-kappaB signaling pathways . Biochem Biophys Res Commun 2002;297: 1277-1281 .[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Zheng C., Xiang J., Hunter T., Lin A.: The JNKK2-JNK1 fusion protein acts as a constitutively active c-Jun kinase that stimulates c-Jun transcription activity . J Biol Chem 1999;274: 28966-28971 .[Abstract/Free Full Text]
- Zentrich E., Han SY, Pessoa-Brandao L., Butterfield L., Heasley LE: Collaboration of JNKs and ERKs in nerve growth factor regulation of the neurofilament light chain promoter in PC12 cells . J Biol Chem 2002; 277: 4110-4118 .[Abstract/Free Full Text]
- Huston JS, Levinson D., Mudgett-Hunter M., Tai MS, Novotny J., Margolies MN, et al: Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli . Proc Natl Acad Sci U S A 1988;85: 5879-5883 .[Abstract/Free Full Text]
- Hazen RJ, Harvey RJ, St. Clair MH, Ferris RG, Freeman GA, Tidwell JH, et al: Anti-human immunodeficiency virus type 1 activity of the nonnucleoside reverse transcriptase inhibitor GW678248 in combination with other antiretrovirals against clinical isolate viruses and in vitro selection for resistance . Antimicrob Agents Chemother 2005;49: 4465-4473 .[Abstract/Free Full Text]
- Gollin SM: Chromosomal instability . Curr Opin Oncol 2004;16: 25-31 .[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Suda M., Ishii T., Sootome H., Shibahara M., Yamashita K., Nobuhiro N., et al: Cell-based screening for specifically detecting kinase activity . Biotechniques. Forthcoming.
- Zhao B., Bower MJ, McDevitt PJ, Zhao H., Davis ST, Johanson KO, et al: Structural basis for Chk1 inhibition by UCN-01 . J Biol Chem 2002; 277: 46609-46615 .[Abstract/Free Full Text]
- Warren GL, Andrews CW, Capelli AM, Clarke B., LaLonde J., Lambert MH, et al: A critical assessment of docking programs and scoring functions . J Med Chem 2006;49: 5912-5931 .[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Yue TL, Gu JL, Wang C., Reith AD, Lee JC, Mirabile RC, et al: Extracellular signal-regulated kinase plays an essential role in hypertrophic agonists, endothelin-1 and phenylephrine-induced cardiomyocyte hypertrophy . J Biol Chem 2000;275: 37895-37901 .[Abstract/Free Full Text]
- Wang XJ, Liefer KM, Tsai S., O'Malley BW, Roop DR: Development of gene-switch transgenic mice that inducibly express transforming growth factor beta1 in the epidermis . Proc Natl Acad Sci U S A 1999;96: 8483-8488 .[Abstract/Free Full Text]
- Zhang JH, Chung TD, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high-throughput screening assays . J Biomol Screen 1999;4: 67-73 .[Abstract/Free Full Text]
- Cheng Y., Prusoff WH: Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction . Biochem Pharmacol 1973;22: 3099-3108 .[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Knight ZA, Shokat KM: Features of selective kinase inhibitors . Chem Biol 2005;12: 621-637 .[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Kubbutat MH, Vousden KH: Proteolytic cleavage of human p53 by calpain: a potential regulator of protein stability . Mol Cell Biol 1997;17: 460-468 .[Abstract]
- Oliner JD, Pietenpol JA, Thiagalingam S., Gyuris J., Kinzler KW, Vogelstein B.: Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53 . Nature 1993;362: 857-860 .[CrossRef][Medline]
[Order article via Infotrieve]
This version was published on September
1, 2007
Journal of Biomolecular Screening, Vol. 12, No. 6,
809-817 (2007)
DOI: 10.1177/1087057107303323

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati Twitter What's this?
|
|